Brief: Merck reports better-than-expected Q1 results

Prometheus Biosciences

27/04/2023 11:30

April 27 (Reuters) - Merck & Co Inc  MRK.N :
    * MERCK QTRLY ADJUSTED EARNINGS PER SHARE $1.40 VERSUS
ESTIMATE
$1.32
    * MERCK QTRLY SALES $14.49 BILLION VERSUS ESTIMATE $13.78
BILLION
    * MERCK QTRLY EARNINGS PER SHARE $1.11
    * MERCK - RAISES AND NARROWS FY ADJUSTED EARNINGS PER SHARE
FORECAST TO BETWEEN $6.88 AND $7.00
    * MERCK - LOWERS & NARROWS FY EARNINGS PER SHARE FORECAST TO
BETWEEN $5.85 AND $5.97, REFLECTING ZETIA ANTITRUST LITIGATION
SETTLEMENT
    * MERCK - RAISES AND NARROWS FY SALES FORECAST TO BETWEEN
$57.7
BILLION AND $58.9 BILLION
    * FY2023 EARNINGS PER SHARE VIEW $6.91, REVENUE VIEW $58.28
BILLION -- REFINITIV IBES DATA
    * MERCK QTRLY KEYTRUDA SALES $5.80 BILLION VERSUS $4.81
BILLION
YEAR AGO
    * MERCK QTRLY GARDASIL/GARDASIL 9 SALES $1.97 BILLION VERSUS
$1.46
BILLION YEAR AGO
    * MERCK QTRLY LAGEVRIO SALES $392 MILLION VERSUS $3.25
BILLION
YEAR AGO
    * MERCK - FY SALES FORECAST INCLUDES ABOUT $1 BILLION OF
LAGEVRIO
SALES
    * MERCK - QTRLY RESULTS INCLUDE $0.52 OF CHARGES RELATED TO
ACQUISITION OF IMAGO, COLLABORATION & LICENSING DEAL WITH
KELUN-BIOTECH
    * MERCK - FY OUTLOOK DOES NOT REFLECT IMPACT OF PROMETHEUS
BIOSCIENCES DEAL, WHICH WOULD LEAD TO ONE-TIME CHARGE OF ABOUT
$10.3 BILLION OR $4/SHARE
    * MERCK - SEES EPS TO BE NEGATIVELY IMPACTED BY ABOUT $0.25
IN
FIRST 12 MONTHS AFTER PROMETHEUS DEAL CLOSE
    * MERCK - PROPOSED PROMETHEUS BIOSCIENCES DEAL EXPECTED TO
CLOSE
IN Q3